Anzahl der Publikationen: 12
2021
Stoetzer, Oliver; Di Gioia, Dorit; Harbeck, Nadia; Salat, Christoph; Mansmann, Ulrich ORCID: https://orcid.org/0000-0002-9955-8906; Harbeck, Nadia; Würstlein, Rachel; Edler von Koch, Franz; Hamann, M.; Braun, M.; Gluz, O.; Lindner, Lars H.; Abdel-Rahman, Sultan und Issels, Rolf D.
(2021):
Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute Experience.
In: Breast Care, Bd. 16, Nr. 2: S. 173-180
Schrodi, S.; Braun, M.; Andrulat, A.; Harbeck, N.; Mahner, S.; Kiechle, M.; Klein, E.; Schnelzer, A.; Schindlbeck, C.; Bauerfeind, I.; Schubert-Fritschle, Gabriele; Nekljudova, V.; Mayr, D.; Weichert, W.; Denkert, C.; Loibl, S. und Engel, J.
(2021):
Outcome of breast cancer patients with low hormone receptor positivity. Analysis of a 15-year population-based cohort.
In: Annals of Oncology, Bd. 32, Nr. 11: S. 1410-1424
[PDF, 1MB]
2020
2017
Nitz, U. A.; Gluz, O.; Christgen, M.; Grischke, E.-M.; Augustin, D.; Kümmel, S.; Braun, M.; Potenberg, J.; Kohls, A.; Krauss, K.; Stefek, A.; Schumacher, C.; Forstbauer, H.; Reimer, T.; Fischer, H.; Liedtke, C.; Würstlein, R.; Schumacher, J.; Kates, R.; Kreipe, H. und Harbeck, N.
(2017):
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab +/- weekly paclitaxel.
In: Annals of Oncology, Bd. 28, Nr. 11: S. 2768-2772
Harbeck, N.; Nitz, U. A.; Matthias, C.; Kates, R.; Braun, M.; Kümmel, S.; Schumacher, C.; Potenberg, J.; Kraemer, S.; Kleine-Tebbe, A.; Augustin, D.; Aktas, B.; Forstbauer, H.; Tio, J.; Liedtke, C.; Grischke, E.-M.; Haas, S. L. de; Deurloo, R.; Schumacher, J.; Würstlein, R.; Kreipe, H. H. und Gluz, O.
(2017):
The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 +/- endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC).
In: Cancer Research, Bd. 77
2016
Gluz, O.; Nitz, U.; Liedtke, C.; Christgen, M.; Sotlar, K.; Grischke, E. M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Lindner, C.; Kuemmel, S.; Clemens, M.; Potenberg, J.; Staib, P.; Kohls, A.; Pelz, E.; Kates, R. E.; Wuerstlein, R.; Kreipe, H. H. und Harbeck, N.
(2016):
Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial.
In: Cancer Research, Bd. 76
Harbeck, N.; Gluz, O.; Christgen, M.; Braun, M.; Kuemmel, S.; Schumacher, C.; Potenberg, J.; Kraemer, S.; Kleine-Tebbe, A.; Augustin, D.; Aktas, B.; Forstbauer, H.; Tio, J.; Liedtke, C.; Kates, R. E.; Wuerstlein, R.; Haas, S. L. de; Kiermaier, A.; Kreipe, H. H. und Nitz, U.
(2016):
Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: Efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab plus endocrine therapy in HER2-positive hormone-receptor positive early breast cancer.
In: Cancer Research, Bd. 76
Gluz, O.; Nitz, U.; Liedtke, C.; Christgen, M.; Sotlar, K.; Grischke, E. M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Lindner, C.; Kuemmel, S.; Clemens, M.; Potenberg, J.; Staib, P.; Kohls, A.; Pelz, E.; Kates, R. E.; Wuerstlein, R.; Kreipe, H. H. und Harbeck, N.
(2016):
Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial.
In: Cancer Research, Bd. 76
Braun, M.; Gluz, O.; Nitz, U.; Christgen, M.; Kuemmel, S.; Schumacher, C.; Potenberg, J.; Kraemer, S.; Kleine-Tebbe, A.; Augustin, D.; Aktas, B.; Forstbauer, H.; Tio, J.; Liedtke, C.; Kates, R. E.; Wuerstlein, R.; Kreipe, H.-H. und Harbecks, N.
(2016):
Final analysis of WSG-ADAPT HER2+/HR+ phase-II-trial - efficacy, safety and predictive markers for 12-weeks of neoadjuvant T-DM1 with or without endocrine therapy versus Trastuzumab plus endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer.
In: Oncology Research and Treatment, Bd. 39: S. 2
Liedtke, C.; Gluz, O.; Nitz, U.; Christgen, M.; Sotlar, K.; Grischke, E.-M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Linder, C.; Kümmel, S.; Clemens, M.; Potenberg, J.; Peter, S.; Kohls, A.; Pelz, E.; Kates, R. E.; Würstlein, R.; Kreipe, H. und Harbeck, N.
(2016):
Comparison of 12 weeks neoadjuvant Nab-Paclitaxel combined with Carboplatinum vs. Gemcitabine in triple negative breast cancer: WSG-ADAPT TN randomized phase II trial.
In: Oncology Research and Treatment, Bd. 39: S. 53
2014
Trojanowski, P.; Plotner, Josef; Grunewald, C.; Graupner, Franziska F.; Slavov, C.; Reuss, A. J.; Braun, M.; Engels, J. W. und Wachtveitl, J.
(2014):
Photo-physical properties of 2-(1-ethynylpyrene)-adenosine: influence of hydrogen bonding on excited state properties.
In: Physical Chemistry, Chemical Physics, Bd. 16, Nr. 27: S. 13875-13888
[PDF, 2MB]
1991
Diese Liste wurde am
Sat Nov 23 21:43:16 2024 CET
erstellt.